Logo do repositório
 
Publicação

A review of national guidelines for management of COPD in Europe

2016-02-01Artigo científico Acesso aberto
Ver registo simples
dc.contributor.authorMiravitlles, Marc
dc.contributor.authorVogelmeier, Claus
dc.contributor.authorRoche, Nicolas
dc.contributor.authorHalpin, David
dc.contributor.authorCardoso, João
dc.contributor.authorChuchalin, Alexander G.
dc.contributor.authorKankaanranta, Hannu
dc.contributor.authorSandström, Thomas
dc.contributor.author͆liwiński, Paweł
dc.contributor.authorZatloukal, Jaromir
dc.contributor.authorBlasi, Francesco
dc.contributor.institutionNOVA Medical School|Faculdade de Ciências Médicas (NMS|FCM)
dc.contributor.pblEuropean Respiratory Society
dc.date.accessioned2024-06-20T00:38:22Z
dc.date.available2024-06-20T00:38:22Z
dc.date.issued2016-02-01
dc.descriptionPublisher Copyright: Copyright © 2016 by the European Respiratory Society.
dc.description.abstractThe quality of care can be improved by the development and implementation of evidencebased treatment guidelines. Different national guidelines for chronic obstructive pulmonary disease (COPD) exist in Europe and relevant differences may exist among them. This was an evaluation of COPD treatment guidelines published in Europe and Russia in the past 7 years. Each guideline was reviewed in detail and information about the most important aspects of patient diagnosis, risk stratification and pharmacotherapy was extracted following a standardised process. Guidelines were available from the Czech Republic, England and Wales, Finland, France, Germany, Italy, Poland, Portugal, Russia, Spain and Sweden. The treatment goals, criteria for COPD diagnosis, consideration of comorbidities in treatment selection and support for use of long-acting bronchodilators, were similar across treatment guidelines. There were differences in measures used for stratification of disease severity, consideration of patient phenotypes, criteria for the use of inhaled corticosteroids and recommendations for other medications (e.g. theophylline and mucolytics) in addition to bronchodilators. There is generally good agreement on treatment goals, criteria for diagnosis of COPD and use of longacting bronchodilators as the cornerstone of treatment among guidelines for COPD management in Europe and Russia. However, there are differences in the definitions of patient subgroups and other recommended treatments.en
dc.description.versionpublishersversion
dc.description.versionpublished
dc.format.extent13
dc.format.extent354570
dc.identifier.doi10.1183/13993003.01170-2015
dc.identifier.issn0903-1936
dc.identifier.otherPURE: 92617575
dc.identifier.otherPURE UUID: 680aa43c-5552-4bde-a652-9d65368fd5ad
dc.identifier.otherScopus: 84958078679
dc.identifier.otherPubMed: 26797035
dc.identifier.urihttp://hdl.handle.net/10362/168815
dc.identifier.urlhttps://www.scopus.com/pages/publications/84958078679
dc.language.isoeng
dc.peerreviewedyes
dc.subjectPulmonary and Respiratory Medicine
dc.titleA review of national guidelines for management of COPD in Europeen
dc.typejournal article
degois.publication.firstPage625
degois.publication.issue2
degois.publication.lastPage637
degois.publication.titleEuropean Respiratory Journal
degois.publication.volume47
dspace.entity.typePublication
rcaap.rightsopenAccess

Ficheiros

Principais
A mostrar 1 - 1 de 1
Miniatura
Nome:
625.full.pdf
Tamanho:
346.26 KB
Formato:
Adobe Portable Document Format
Ver/Abrir

Coleções

NMS - Artigos em revista internacional com arbitragem científica